अरबिंदो फार्मा शेयर की कीमत

<h3><span style="font-size:16px;"><strong>फार्मास्यूटिकल्स कंपनी अरबिंदो फार्मा ने Q1FY27 परिणामों की घोषणा की</strong></span></h3><p><strong _ngcontent-ng-c1006311636="">कंसोलिडेटेड फाइनेंशियल हाइलाइट्स:</strong></p><ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Revenue from Operations:</strong> Stood at Rs 91,503.5 million, representing a YoY growth of 16.3% compared to Rs 78,681.4 million in Q1FY26 and a QoQ increase of 3.35% from Rs 88,533.4 million in Q4FY26.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Income:</strong> Reached Rs 94,145.8 million, up 18.08% YoY from Rs 79,734.4 million and up 4.95% QoQ from Rs 89,703.8 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Profit Before Tax (PBT):</strong> Reported at Rs 15,150.9 million, an increase of 25.55% YoY from Rs 12,068.0 million and a growth of 17.4% QoQ from Rs 12,906.1 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Profit After Tax (PAT):</strong> Net profit attributable to owners of the parent company was Rs 10,325.6 million, marking a YoY growth of 25.2% from Rs 8,247.5 million and a QoQ growth of 12.08% from Rs 9,212.6 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Earnings Per Share (EPS):</strong> Basic and diluted EPS stood at Rs 17.86 for the quarter, compared to Rs 14.20 in Q1FY26 and Rs 15.86 in Q4FY26.</li></ul><p><strong _ngcontent-ng-c1006311636="">स्टैंडअलोन फाइनेंशियल हाइलाइट्स:</strong></p><ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Revenue from Operations:</strong> Stood at Rs 27,995.1 million, reflecting a YoY decline of 1.71% from Rs 28,481.7 million, but a marginal QoQ increase of 0.47% from Rs 27,865.5 million in Q4FY26.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Income:</strong> Reached Rs 30,414.0 million, up 3.73% YoY from Rs 29,319.4 million and up 1.36% QoQ from Rs 30,006.4 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Profit Before Tax (PBT):</strong> Reported at Rs 10,080.8 million, an increase of 34.39% YoY from Rs 7,500.9 million and a growth of 15.04% QoQ from Rs 8,763.1 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Profit After Tax (PAT):</strong> Net profit for the quarter was Rs 7,372.2 million, up 31.85% YoY from Rs 5,591.3 million and up 6.5% QoQ from Rs 6,922.3 million.</li></ul><p><strong _ngcontent-ng-c1006311636="">बिज़नेस हाइलाइट्स:</strong></p><ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">US Revenue:</strong> Increased by 8.1% YoY to Rs 37,700 million, primarily driven by volume gains and new launches, and grew 6.4% QoQ from Rs 35,430 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Europe Revenue:</strong> Grew significantly by 25.6% YoY to Rs 29,370 million, accounting for 32.1% of consolidated revenue, and grew 5.1% QoQ from Rs 27,950 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Growth Markets Revenue:</strong> Saw a robust growth of 37.7% YoY to Rs 10,630 million and an 8.5% QoQ increase from Rs 9,800 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">ARV Revenue:</strong> Stood at Rs 3,300 million, a YoY decrease of 6.9% but a marginal QoQ increase of 0.8% compared to Q4FY26.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Active Pharmaceutical Ingredients (API) Revenue:</strong> Grew by 14.6% YoY to Rs 10,490 million, although it saw a sequential QoQ decline of 13.1% from Rs 12,080 million due to seasonal softness in the antibiotics portfolio.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Acquisitions & Buyback:</strong> The company completed the acquisition of 100% membership interest in Lannett Company LLC on June 29, 2026. Additionally, the company approved a buyback of equity shares for an aggregate value not exceeding Rs 8,000 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Product Approvals:</strong> Received final approval for 10 products from USFDA during the quarter.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Cash Flow:</strong> Generated free cash flow of USD 98 million during the quarter.</li></ul><p _ngcontent-ng-c1006311636=""><strong>K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company, said:</strong> “We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio. While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives and create sustained value for our stakeholders.”</p><p><a class="lb" href="/hindi/get-document/post/pdf/5767771/" target="_blank">परिणाम PDF</a></p>

• ट्रेंडलाइन
• 3 घंटे 43 मिनट पहले

Broad-based growth across business segments helped the drugmaker deliver record quarterly sales and stronger profitability despite a dynamic global operating environment

• बिज़नेस लाइन
• 17 घंटे 21 मिनट पहले

Intimation of proposal of merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary.

• बीएसई इंडिया
• 19 घंटे 58 मिनट पहले